No Detail Found!

High Creatinine Level Secondary to Use of CDK 4/6 Inhibitor Treatment (Palbociclib and Ribociclib) + Endocrine Therapy (ET)

Author(s)
Merve Keskinkilic Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkiye
Huseyin Salih Semiz Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkiye
Tugba Yavuzsen Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkiye
Aziz Karaoglu Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkiye
Abstract
The aim of this study is to share real-life data on the increase in creatinine due to CDK 4/6 inhibitor treatment and patients diagnosed with HR+/HER2-MBC and treated with ribociclib or palbociclib combined with ET were included in the study. While creatinine increase was observed in 17.9% (n = 19) of the 106 patients in the study population, 8.5% (n = 9) had Grade 1, 8.5% (n = 8) had Grade 2, and % 0.9 (n = 1) had Grade 3 creatinine elevation. The increase in creatinine occurred in 25% (n = 12) of ribociclib users and 12.1% (n = 7) of palbociclib users. No patient required a dose reduction or discontinuation of treatment due to elevated creatinine. Of the patients with high creatinine levels, 36.8% (n = 7) were over 65 years of age. Those with multiple comorbidities, blood urea nitrogen (BUN) >13.5 mg/dl, creatinine >0.66 mg/dl, BUN/creatinine ratio >19.95, glomerular ltration rate (GFR) >96.05 ml/min, and uric acid >4.69mg/dl. It was observed that the increase in the creatinine level was statistically signi cant (p <0.001). In conclusion, this study revealed that the increase in the serum creatinine secondary to ribociclib and palbociclib treatments is associated with kidney function tests and the number of concomitant diseases.
Publication Details
Page(s) 851-853
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 7, Year: 2024

Request the full text from PASTIC

Keywords
CDK 4/6 inhibitor, Palbociclib, Creatinine elevation, Ribociclib
0

Citations

0

Downloads

51

Views